Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-REG OUTCOME cardiovascular safety study in type 2 diabetes
2009-016178-33Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Primary composite cardiovascular endpoint and Composite adjudicated cardiovascular events. Started Apr 2010; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-016178-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016178-33.